Skip to content

Clinical trials

Breast Neoplasms trials in Mexico with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Neoplasms Phase: Not applicable Country / region: Mexico Clear all

18 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20071
20151
20161
20213
20222
20234
20253
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Recruiting2
Unknown status2
Withdrawn1
Not yet recruiting1
Enrolling by invitation1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Medicos e Investigadores en la Lucha contra el Cancer de Mama5
Instituto Nacional de Cancerologia de Mexico2
Anahuac Mayab University1
Coordinación de Investigación en Salud, Mexico1
Humberto Francisco Astiazaran Garcia, PhD1
Instituto Jalisciense de Cancerologia1
Instituto Mexicano del Seguro Social1
Instituto Nacional de Cardiologia Ignacio Chavez1
Memorial Sloan Kettering Cancer Center1
National Institute of Cancerología1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms18
Anxiety Disorders2
Thyroid Neoplasms2
Adenoma, Islet Cell1
Breast Carcinoma In Situ1
Carcinoma, Hepatocellular1
Carcinoma, Intraductal, Noninfiltrating1
Carcinoma, Non-Small-Cell Lung1
Carcinoma, Renal Cell1
Cardiotoxicity1

Trials

Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.